Nexalin Technology (NXL) Revenue (QoQ) (2021 - 2026)
Nexalin Technology (NXL) Revenue (QoQ) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.07 Bn | 193.46 Bn | 7.27 Bn |
| 2 | Stryker | 127.90 Bn | 124.43 Bn | 4.50 Bn |
| 3 | Medtronic | 118.84 Bn | 109.62 Bn | 6.41 Bn |
| 4 | Boston Scientific | 73.33 Bn | 72.79 Bn | 3.85 Bn |
| 5 | Edwards Lifesciences | 51.93 Bn | 47.68 Bn | 1.35 Bn |
| 6 | Dexcom | 34.46 Bn | 32.51 Bn | 830.00 Mn |
| 7 | GE HealthCare Technologies | 33.91 Bn | 31.81 Bn | 2.18 Bn |
| 8 | Koninklijke Philips | 26.36 Bn | 23.04 Bn | 4.55 Bn |
| 9 | Steris | 23.12 Bn | 22.64 Bn | 684.20 Mn |
| 10 | Nexalin Technology | 6.98 Mn | 5.97 Mn | 8,897.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -18.66% |
| Mar 31, 2026 | -91.30% |
| Dec 31, 2025 | 847.13% |
| Sep 30, 2025 | -74.29% |
| Jun 30, 2025 | 72.10% |
| Mar 31, 2025 | 50.91% |
| Dec 31, 2024 | -24.57% |
| Sep 30, 2024 | 34.24% |
| Jun 30, 2024 | -65.88% |
| Mar 31, 2024 | 283.09% |
| Dec 31, 2023 | -14.83% |
| Sep 30, 2023 | -32.15% |
| Jun 30, 2023 | 16.30% |
| Mar 31, 2023 | -20.47% |
| Dec 31, 2022 | -92.95% |
| Sep 30, 2022 | 31.63% |
| Jun 30, 2022 | 28.13% |
| Mar 31, 2022 | 1,247.23% |
| Dec 31, 2021 | -57.12% |